Learning Task-Specific Antibody Representations via Function-Aware Masking

Antibody-specific language models pretrained via masked language modeling (MLM) learn representations that are critical for downstream sequence design and property prediction tasks. Yet, the corruption process itself is rarely leveraged as a source of inductive bias during pretraining. While preferentially masking complementarity-determining regions (CDRs) improves binding-related predictions, antibodies possess diverse biological priors over a variety of functions. Herein, we introduce function-aware masking, a family of pretraining algorithms that align mask placement with specific functional priors (e.g., from IMGT annotations or structure predictions) to shape the learned representation space. We show that these specialist masking strategies significantly improve performance on their respective objectives, yielding up to a 14% gain on structure-related tasks and up to a 5.9x improvement on CDR-related tasks. To further improve performance across multiple functional axes, we develop hybrid masking strategies that integrate multiple priors, balancing reconstruction over binding, structural, and biophysical objectives. Our results demonstrate that informed mask placement provides a parameter-free mechanism for imposing functional inductive biases in antibody language model training.

Antigen-specific Antibody Multi-modal Foundation Model for Functional Antibody Design

Antibodies are essential proteins that play a central role in immune recognition by binding specific antigen molecules. Although recent protein language models have enabled progress in single-chain protein modeling and generation, they often fall short in antigen-specific antibody design, where effective modeling requires explicit pairing between antibody and antigen, particularly at the epitope level. To address these limitations, we introduce AAMFM, an Antigen-specific Antibody Multimodal Foundation Model that learns unified representations of antibody sequences and structures conditioned on antigen context. AAMFM incorporates rich antigen information including geometric interfaces and epitope annotations via a cross-modal adapter, enabling joint modeling of antibody-antigen interactions in a shared latent space. To further guide the model toward functional relevance, we fine-tune AAMFM using Calibrated Direct Preference Optimization (Cal-DPO), leveraging preference signals extracted from a strong structural prior to align learning with binding-specific objectives. Extensive experiments demonstrate that AAMFM achieves state-of-the-art performance in functional antibody design, revealing its potential for antigen-specific antibody engineering. Our code is available at https://github.com/XL-S224/AAMFM.

ABOPD: Antibody CDR Design via On-Policy Distillation

Antibodies are essential therapeutic molecules, and their complementarity-determining regions (CDRs) form the primary antigen-recognition interface. Recent protein generative models have demonstrated broad capabilities in biomolecular design, yet post-training strategies for downstream objectives remain limited. Standard denoising training operates on noisy states obtained by perturbing native structures, whereas recursive generation proceeds through model-generated intermediate states. For flexible antibody CDR loops such as CDR-H3, this mismatch can allow backbone deviations to accumulate along the denoising trajectory and compromise antigen-facing loop geometry. We introduce ABOPD, an antibody design framework based on on-policy distillation that leverages privileged native geometry during training to supervise states visited along the model's own denoising trajectories. With this fine-grained structural supervision, ABOPD substantially improves structural recovery on RAbD CDR-H3 generation, reducing RMSD by 0.42 Å (from 2.37 Å to 1.95 Å) and outperforming supervised fine-tuning and offline distillation controls, offering a path to higher-fidelity protein design.

Preference-based Antibody Expression Ranking: Scaling with Large-scale Weak Supervision

Antibody expression ranking is a critical task in antibody design, yet its modelling is severely hindered by the scarcity of labeled experimental data. To address this, we propose a unified preference-based learning framework that integrates scarce quantitative expression data with large-scale weak positive supervision from immunization data. We adapt Direct Preference Optimization (DPO) to protein language models by introducing a union-masked log-likelihood approximation and IMGT-based alignment, enabling efficient training on variable-length sequences. Evaluating on a diverse internal dataset of 1254 labeled sequences and 4 million unlabeled camelid-derived antibodies, we show that our method consistently outperforms baselines on most metrics. Our results demonstrate that preference learning can effectively learn from weak supervision, providing a scalable solution for antibody expressibility optimization in data-constrained settings. Project page: https://kisoji-biotechnology-inc.github.io/Preference-Expression-Ranking/.

EvoStruct: Bridging Evolutionary and Structural Priors for Antibody CDR Design via Protein Language Model Adaptation

Equivariant graph neural network (GNN) methods for antibody complementarity-determining region (CDR) design achieve the highest sequence recovery but suffer from severe vocabulary collapse. The current best GNN methods over-predict very few amino acids, such as tyrosine and glycine, while ignoring functionally important residues. We trace this failure to GNN encoders learning amino acid distributions de novo from limited structural data, discarding substitution patterns encoded in evolutionary databases. To resolve this, we propose EvoStruct, which bridges a frozen protein language model (PLM) with 3D structural context from an E(3)-equivariant GNN via a cross-attention adapter. Unlike prior PLM-structure adapters for general protein design, EvoStruct targets the vocabulary collapse problem specific to CDR design through progressive PLM unfreezing and R-Drop consistency regularization. On the CHIMERA-Bench dataset, EvoStruct achieves the highest amino acid recovery and lowest perplexity among several antibody design methods, improving sequence recovery by 16% and reducing perplexity by 43% relative to the best GNN baselines, while recovering 2.3x greater amino acid diversity and the highest binding-pair correlation with ground truth.